Oppenheimer Lifts Target on Celldex Therapeutics (CLDX) on Final Phase IIb CDX-011 Data
Tweet
Share
E-mailGet Alerts CLDX Hot Sheet
Price: $41.95 -1.55%
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer boosted its price target on Outperform-rated Celldex Therapeutics (NASDAQ: CLDX) from $8 to $10 following final data from the Phase IIb (EMERGE) of CDX-011 in metastatic breast cancer (BC) were.
The firm notes, "CDX-011 was well tolerated and the response rate in triple negative BC was 19% compared to 0% for the investigator's choice (IC) arm. High GPNMB expressing tumors had a CDX-011 response rate of 32% vs. 13% for IC. Although EMERGE was not designed to show overall survival (OS), there was a trend toward OS across all patients. The high GPNMB expressing triple negative subgroup achieved statistically significant improvement in progression free survival (PFS) and OS. Celldex is planning to meet with the FDA later this month to discuss the registration strategy."
For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.
Shares of Celldex Therapeutics closed at $5.52 yesterday.
The firm notes, "CDX-011 was well tolerated and the response rate in triple negative BC was 19% compared to 0% for the investigator's choice (IC) arm. High GPNMB expressing tumors had a CDX-011 response rate of 32% vs. 13% for IC. Although EMERGE was not designed to show overall survival (OS), there was a trend toward OS across all patients. The high GPNMB expressing triple negative subgroup achieved statistically significant improvement in progression free survival (PFS) and OS. Celldex is planning to meet with the FDA later this month to discuss the registration strategy."
For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.
Shares of Celldex Therapeutics closed at $5.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Petronet LNG Ltd. (PLNG:IN) PT Raised to INR310 at ICICI Securities
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
